Oseltamivir reduces duration and complications of influenza
the ONA take:
According to a new study published in the journal The Lancet, researchers at the University of Michigan, the University of Alabama, and the London School of Hygiene and Tropical Medicine have found that oseltamivir, a neuraminidase inhibitor, decreases the duration of influenza symptoms by about 1 day and decreases possible respiratory infections by 44%.
For the meta-analysis, researchers identified clinical trials conducted between 1997 and 2001. The studies included over 4,300 patients with more than half being treated with oseltamivir for influenza.
Results showed that when patients took oseltamivir 75mg twice daily within 36 hours of developing at least two flu symptoms, oseltamivir decreased the duration of the flu by 21%.
Patients who took oseltamivir experienced symptom alleviation at 98 hours versus 123 hours for those who took placebo.
In addition, researchers found that 4.9% of those who took oseltamivir had respiratory complications compared with 8.7% of those who took placebo. Oseltamivir was also shown to reduce hospital admissions by 63%. In regard to safety, oseltamivir increased nausea and vomiting, but did not cause more neurological or psychological disorders than placebo.
Oseltamivir decreases duration of influenza symptoms by about 1 day and decreases possible respiratory infections by 44%.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|